Format

Send to

Choose Destination
Diabetes Metab Syndr Obes. 2017 Aug 14;10:345-361. doi: 10.2147/DMSO.S100074. eCollection 2017.

Novel biomarkers for prediabetes, diabetes, and associated complications.

Author information

1
New York University School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, NYU Langone Medical Center, New York, NY.
2
Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Abstract

The number of individuals with prediabetes is expected to grow substantially and estimated to globally affect 482 million people by 2040. Therefore, effective methods for diagnosing prediabetes will be required to reduce the risk of progressing to diabetes and its complications. The current biomarkers, glycated hemoglobin (HbA1c), fructosamine, and glycated albumin have limitations including moderate sensitivity and specificity and are inaccurate in certain clinical conditions. Therefore, identification of additional biomarkers is being explored recognizing that any single biomarker will also likely have inherent limitations. Therefore, combining several biomarkers may more precisely identify those at high risk for developing prediabetes and subsequent progression to diabetes. This review describes recently identified biomarkers and their potential utility for addressing the burgeoning epidemic of dysglycemic disorders.

KEYWORDS:

biomarkers; diabetes; diabetes complications; inflammatory markers; prediabetes

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center